ATE73321T1 - Zusammensetzung mit verzoegerter abgabe. - Google Patents

Zusammensetzung mit verzoegerter abgabe.

Info

Publication number
ATE73321T1
ATE73321T1 AT86114067T AT86114067T ATE73321T1 AT E73321 T1 ATE73321 T1 AT E73321T1 AT 86114067 T AT86114067 T AT 86114067T AT 86114067 T AT86114067 T AT 86114067T AT E73321 T1 ATE73321 T1 AT E73321T1
Authority
AT
Austria
Prior art keywords
delivery composition
delayed delivery
pharmaceutical
pharmaceutical substance
mammals
Prior art date
Application number
AT86114067T
Other languages
English (en)
Inventor
Keiji Fujioka
Shigeji Sato
Nobuhiko Tamura
Yoshihiro Takada
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61223251A external-priority patent/JPH0761959B2/ja
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE73321T1 publication Critical patent/ATE73321T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT86114067T 1985-10-11 1986-10-10 Zusammensetzung mit verzoegerter abgabe. ATE73321T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP22759085 1985-10-11
JP61223251A JPH0761959B2 (ja) 1985-10-11 1986-09-19 シリコンエラストマ−系徐放性製剤
JP61223250A JPS62174031A (ja) 1985-10-11 1986-09-19 高分子量薬物含有徐放性製剤
EP86114067A EP0219076B1 (de) 1985-10-11 1986-10-10 Zusammensetzung mit verzögerter Abgabe

Publications (1)

Publication Number Publication Date
ATE73321T1 true ATE73321T1 (de) 1992-03-15

Family

ID=27330754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86114067T ATE73321T1 (de) 1985-10-11 1986-10-10 Zusammensetzung mit verzoegerter abgabe.

Country Status (7)

Country Link
US (1) US4985253A (de)
EP (1) EP0219076B1 (de)
AT (1) ATE73321T1 (de)
AU (1) AU594088B2 (de)
DE (1) DE3684220D1 (de)
ES (1) ES2051682T3 (de)
NZ (1) NZ217844A (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
EP0227400B1 (de) * 1985-12-16 1991-12-04 Ethicon, Inc. Hemmung von post-chirurgischer Adhäsionsbildung durch topische Verabreichung von Gewebeplasminogenaktivator
US4761289A (en) * 1986-10-10 1988-08-02 International Minerals & Chemical Corp. Sustained release implant and method for preparing same
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
EP0297860B1 (de) * 1987-07-01 1993-09-01 Genentech, Inc. Therapeutische Zusamensetzungen und Verfahren zur Verhinderung von Fibrinablagerung und Adhäsionen
JPH01186823A (ja) * 1988-01-21 1989-07-26 Dow Corning Kk 薬物透過性物質の製造方法
FR2650502B1 (fr) * 1989-08-07 1994-05-27 Delagrange Laboratoires Nouvelle forme galenique orale ameliorant la biodisponibilite
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
IL110787A0 (en) * 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
DE4409357C2 (de) * 1994-03-18 1996-10-17 Upmeyer Hans Juergen Verwendung von Dimeticon zur Eradikation von Heliobacter pylori
US5834004A (en) * 1994-03-18 1998-11-10 Upmeyer; Hans-Juergen Enteral composition comprising dimethicone and a photosensitizer and a method of delivery
US6028062A (en) * 1995-03-15 2000-02-22 Upmeyer; Hans-Juergen Use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (Hp) associated syndromes and infectious diseases
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
TW586944B (en) 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
BR9913596B1 (pt) * 1998-09-10 2014-12-23 Dainippon Sumitomo Pharma Co Composição farmacêutica de liberação prolongada de droga com longa duração.
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
TW524696B (en) * 1999-11-10 2003-03-21 Sumitomo Pharma Sustained-release drug formulations
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
DK1377320T3 (da) 2001-04-04 2009-02-09 Nordic Vaccine Technology As Polynukleotidbindingskomplekser omfattende steroler og saponiner
ATE372772T1 (de) 2004-07-13 2007-09-15 Schering Oy Retardiertes freigabesystem mit kontrollierter initialabgabe
US7857856B2 (en) * 2005-03-15 2010-12-28 Warsaw Ortho Pedic, Inc. Composite spinal nucleus implant with water absorption and swelling capabilities
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US8419793B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
US8420153B2 (en) * 2008-09-19 2013-04-16 Mentor Worldwide Llc Coating with antimicrobial agents
CN103140226B (zh) 2010-08-06 2015-07-08 大日本住友制药株式会社 用于治疗脊髓损伤的制剂
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
EP4100075A4 (de) 2020-03-20 2024-01-31 The Regents of University of California Implantierbare wirkstofffreisetzungsvorrichtungen zur lokalisierten wirkstofffreisetzung

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US3545439A (en) * 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US4004979A (en) * 1968-03-29 1977-01-25 Agence Nationale De Valorisation De La Recherche (Anvar) Preparation of active proteins cross-linked to inactive proteins
US4464468A (en) * 1968-03-29 1984-08-07 Agence Nationale De Valorisation De La Recherche (Anvar) Immobilization of active protein by cross-linking to inactive protein
BE791632A (fr) * 1971-11-20 1973-05-21 Schering Ag Supports a base de caoutchouc siliconique pour agents medicamenteux
DE2445971A1 (de) * 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
EP0000938B1 (de) * 1977-08-22 1984-10-17 National Research Development Corporation Makromolekulare kovalente Konjugate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
US4478596A (en) * 1982-11-26 1984-10-23 Michelson Paul E Delivery system for physiologically active agents
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
DE3484951D1 (de) * 1983-10-14 1991-09-26 Sumitomo Pharma Verlaengerte praeparate mit verzoegerter abgabe.
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
US4559054A (en) * 1984-08-09 1985-12-17 Research Corporation Rate-controlled drug release system
AU561608B1 (en) * 1985-11-04 1987-05-14 Paco Research Corp. Transdermal vasoactive delivery

Also Published As

Publication number Publication date
AU594088B2 (en) 1990-03-01
ES2051682T3 (es) 1994-07-01
US4985253A (en) 1991-01-15
AU6385486A (en) 1987-04-16
NZ217844A (en) 1989-10-27
EP0219076A3 (en) 1988-04-20
EP0219076B1 (de) 1992-03-11
EP0219076A2 (de) 1987-04-22
DE3684220D1 (de) 1992-04-16

Similar Documents

Publication Publication Date Title
DE3684220D1 (de) Zusammensetzung mit verzoegerter abgabe.
DK203787D0 (da) Praeparat til nasal administrering
DK0871476T3 (da) Tørret blodfaktorpræparat indeholdende trehalose
IT1231434B (it) Composizione farmaceutica endovenosa e procedimento per la sua preparazione.
IT8467445A1 (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea.
ITRM930840A0 (it) Composizione teapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
NO873243L (no) Legemiddel med antitumorvirkning.
NO862507L (no) Faste, holdbare administreringsformer med elastisk filmovertrekk.
DK0879056T3 (da) Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter
DK561089D0 (da) Anvendelse af lactamimider til fremstilling af laegemidler
DK396286D0 (da) Injicerbar formulering med forsinket frigivelse af den aktive bestanddel
IT1232819B (it) Impiego di sorgenti di nucleobasi per stimolare la funzione immunitaria, relativo procedimento e composizioni farmaceutiche contenenti una tale sorgente di nucleobasi
FI863078A0 (fi) Kontinuerligt frigoerande peptidkompositioner.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
DK264787A (da) Anvendelse af humant alfa-interferon til fremstilling af et pharmaceutisk praeparat
ATE58829T1 (de) Mittel mit kontinuierlicher freisetzung von phenylethanolaminderivaten.
IT1209323B (it) Sostanza biologicamente attiva, conproprieta'immuno-stimolanti,sua preparazione e medicamenti che la con tengono per aumentare la resistenza verso le infezioni
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
IT8523530V0 (it) Dispositivo perfezionato per somministrazione medicinali iniettabili.
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
ES8704874A1 (es) Procedimiento de preparacion de nuevos derivados de acetilmetadol y de propoxifeno
ATE82138T1 (de) Geregelte verabreichungszusammensetzung.
MX170792B (es) Composicion de liberacion sostenida
ES1015531Y (es) Jeringuilla perfeccionada de unica utilizacion.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time